Coloplast's valuation has been adjusted to a 20x price-to-earnings ratio with a new target price of 490 DKK, reflecting a more realistic outlook after premiumization effects were removed. Despite recent challenges such as the Kerecis acquisition write-down, product recalls, and regulatory changes, the company's core fundamentals and demand remain strong. The stock now trades at a historically low sub-18x P/E, offering a 5.76% dividend yield and potential annual growth of 12-13% through 2028. Risks include geopolitical tensions, regulatory unpredictability, and margin pressures, but these appear priced in, supporting a buy rating for investors.
ImPact Biotech announced updated Phase 3 ENLIGHTED trial results showing 70% complete response in patients with low-grade upper tract urothelial carcinoma (UTUC) treated with Padeliporfin VTP. The treatment demonstrated durable effects, with 85.7% of...
On May 15, 2026, Drake released a triple album with 43 tracks, including the song "Dust" where he calls himself a "BTC crypto big-timer" and references Sam Bankman-Fried (SBF), urging for his release from prison. This marks Drake's most explicit publ...
CoreWeave expects to exceed a $30 billion annualized revenue run-rate by fiscal year 2027, supported by a $99.4 billion backlog and over 75% contracted capacity for 2027. The company's growth is driven by increasing power capacity and higher pricing ...
Phunware Inc's new CEO, Dimitry Kroshka, introduced the company's strategic vision called Hospitality Tech 2.0, which expands its AI-driven platform for luxury resorts. The platform uses spatial technology to guide guests through complex resort prope...
STAAR Surgical reported strong 1Q26 results, with revenue rising 119% year-over-year to $93.5 million and a net income of $5.2 million, reversing previous losses. Growth was driven by China's market recovery, normalized inventory levels, and rapid ad...
